Abstract
Objective Methadone is an evidence based treatment for opioid use disorder and is also employed for acute pain. The primary objective of this study was to explore methadone distribution patterns between the years 2017 and 2019 across the United States (US). This study builds upon previous literature that has analyzed prior years of US distribution patterns, and further outlines regional and state specific methadone trends.
Methods The Drug Enforcement Administration’s Automated Reports and Consolidated Ordering System (ARCOS) was used to acquire the number of narcotic treatment programs (NTPs) per state and methadone distribution weight in grams. Methadone distribution by weight, corrected for state populations, and number of NTPs were compared from 2017 to 2019 between states, within regions, and nationally.
Results Between 2017 and 2019, the national distribution of methadone increased 12.30% for NTPs but decreased 34.57% for pain, for a total increase of 2.66%. While all states saw a decrease in distribution for pain, when compared regionally, the Northeast showed a significantly smaller decrease than all other regions. Additionally, the majority of states experienced an increase in distribution for NTPs and most states demonstrated a relatively stable or increasing number of NTPs, with an 11.49% increase in NTPs nationally. The number of NTPs per 100K in 2019 ranged from 2.08 in Rhode Island to 0.00 in Wyoming.
Conclusion Although methadone distribution for OUD was increasing in the US, there were pronounced regional disparities.
Competing Interest Statement
BJP is part of an osteoarthritis research team supported by Pfizer. The other authors have no relevant disclosures.
Funding Statement
No external funding specific to this project was received for this research. Software for figures was provided by the National Institute of Environmental Health Sciences (T32 ES007060-31A1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of New England's IRB approved this study as exempt (#20180410-009).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* psy391{at}gmail.com; piper{at}som.geisinger.edu
Conflicts of Interest and Source of Funding: BJP is part of an osteoarthritis research team supported by Pfizer. The other authors have no conflicts of interest to declare.
Data Availability
Raw data in the form of pdfs are available at: https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/ Extracted data from these 5-1,100 page reports is included in the supplemental materials.
https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2019.pdf
